Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date |
Reported DateTime |
Company | Symbol | Insider Relationship |
Shares Traded |
Average Price |
Total Amount |
Shares Owned |
Filing |
| 2022-11-23 Purchase |
2022-11-23 4:05 pm |
Eledon Pharmaceuticals Inc. | ELDN | Perrin Steven President |
1,000 | $2.5969 | $2,597 | 1,000 (Direct) |
View |
| 2021-12-20 Purchase |
2021-12-21 4:05 pm |
Eledon Pharmaceuticals Inc. | ELDN | Gros David-Alexandre C Chief Executive Officer |
2,000 | $4.48 | $8,960 | 9,000 (Direct) |
View |
| 2021-08-17 Purchase |
2021-08-19 4:05 pm |
Eledon Pharmaceuticals Inc. | ELDN | Gros David-Alexandre C Chief Executive Officer |
4,000 | $6.21 | $24,840 | 7,000 (Direct) |
View |
| 2021-06-11 Purchase |
2021-06-14 5:24 pm |
Eledon Pharmaceuticals Inc. | ELDN | Little Paul Sean CHIEF FINANCIAL OFFICER |
10,000 | $8.87 | $88,700 | 10,000 (Direct) |
View |
| 2021-06-09 Purchase |
2021-06-10 5:25 pm |
Eledon Pharmaceuticals Inc. | ELDN | Gros David-Alexandre C Chief Executive Officer |
3,000 | $8.01 | $24,030 | 3,000 (Direct) |
View |
| 2020-12-02 Sale |
2020-12-04 5:17 pm |
Novus Therapeutics Inc. | NVUS | OrbiMed Israel GP Ltd. OrbiMed Israel BioFund GP Limited Partnership 10% Owner |
103,200 | $21.6 | $2,229,120 | 73,650 (Indirect) |
View |
| 2020-10-30 Purchase |
2020-11-06 6:46 pm |
Novus Therapeutics Inc. | NVUS | Logos Global Management LP 10% Owner |
92,040 | $25.44 | $2,341,714 | 224,071 (Indirect) |
View |
| 2020-10-30 Sale |
2020-11-06 6:46 pm |
Novus Therapeutics Inc. | NVUS | Logos Global Management LP 10% Owner |
12,969 | $26.64 | $345,559 | 224,071 (Indirect) |
View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date |
Reported DateTime |
Exercisable Expiration |
Company | Symnbol | Insider Relationship |
Shares Traded |
Conversion Price |
Shares Owned |
Filing |
| 2023-02-01 Option Award |
2023-02-02 6:04 pm |
N/A 2033-02-01 |
Eledon Pharmaceuticals Inc. | ELDN | Katkin Keith Director |
20,000 | $0 | 20,000 (Direct) |
View |
| 2023-02-01 Option Award |
2023-02-02 5:58 pm |
N/A 2033-02-01 |
Eledon Pharmaceuticals Inc. | ELDN | Hillson Jan Director |
20,000 | $0 | 20,000 (Direct) |
View |
| 2023-02-01 Option Award |
2023-02-02 5:56 pm |
N/A 2033-02-01 |
Eledon Pharmaceuticals Inc. | ELDN | Gros David-Alexandre C Chief Executive Officer |
453,600 | $0 | 453,600 (Direct) |
View |
| 2023-02-01 Option Award |
2023-02-02 5:43 pm |
N/A 2033-02-01 |
Eledon Pharmaceuticals Inc. | ELDN | Smith Bryan E. General Counsel, Corporate Sec |
155,000 | $0 | 155,000 (Direct) |
View |
| 2023-02-01 Option Award |
2023-02-02 5:40 pm |
N/A 2033-02-01 |
Eledon Pharmaceuticals Inc. | ELDN | Little Paul Sean Chief Financial Officer |
155,000 | $0 | 155,000 (Direct) |
View |
| 2022-02-01 Option Award |
2022-02-02 5:38 pm |
N/A 2032-02-01 |
Eledon Pharmaceuticals Inc. | ELDN | Gros David-Alexandre C Chief Executive Officer |
108,000 | $0 | 108,000 (Direct) |
View |
| 2022-02-01 Option Award |
2022-02-02 5:37 pm |
N/A 2032-02-01 |
Eledon Pharmaceuticals Inc. | ELDN | Smith Bryan E. General Counsel, Corporate Sec |
120,000 | $0 | 120,000 (Direct) |
View |
| 2022-02-01 Option Award |
2022-02-02 5:37 pm |
N/A 2032-02-01 |
Eledon Pharmaceuticals Inc. | ELDN | Perrin Steven President |
155,000 | $0 | 155,000 (Direct) |
View |
| 2022-02-01 Option Award |
2022-02-02 5:36 pm |
N/A 2032-02-01 |
Eledon Pharmaceuticals Inc. | ELDN | Ogier Walter C Director |
20,000 | $0 | 20,000 (Direct) |
View |
| 2022-02-01 Option Award |
2022-02-02 5:35 pm |
N/A 2032-02-01 |
Eledon Pharmaceuticals Inc. | ELDN | McBride John S. Director |
20,000 | $0 | 20,000 (Direct) |
View |
| 2022-02-01 Option Award |
2022-02-02 5:33 pm |
N/A 2032-02-01 |
Eledon Pharmaceuticals Inc. | ELDN | LYONS GARY A Director |
20,000 | $0 | 20,000 (Direct) |
View |
| 2022-02-01 Option Award |
2022-02-02 5:32 pm |
N/A 2032-02-01 |
Eledon Pharmaceuticals Inc. | ELDN | Lee June Director |
20,000 | $0 | 20,000 (Direct) |
View |
| 2022-02-01 Option Award |
2022-02-02 5:30 pm |
N/A 2032-02-01 |
Eledon Pharmaceuticals Inc. | ELDN | Katkin Keith Director |
20,000 | $0 | 20,000 (Direct) |
View |
| 2022-02-01 Option Award |
2022-02-02 5:29 pm |
N/A 2032-02-01 |
Eledon Pharmaceuticals Inc. | ELDN | Hillson Jan Director |
20,000 | $0 | 20,000 (Direct) |
View |
| 2022-02-01 Option Award |
2022-02-02 5:23 pm |
N/A 2032-02-01 |
Eledon Pharmaceuticals Inc. | ELDN | Little Paul Sean Chief Financial Officer |
155,000 | $0 | 155,000 (Direct) |
View |
Ownership |
2022-01-31 8:52 pm |
N/A N/A |
Eledon Pharmaceuticals Inc. | ELDN | BVF PARTNERS L P BIOTECHNOLOGY VALUE FUND L P BVF I GP LLC BIOTECHNOLOGY VALUE FUND II LP BVF II GP LLC Biotechnology Value Trading Fund OS LP BVF Partners OS Ltd. BVF GP HOLDINGS LLC BVF INC LAMPERT MARK N 10% Owner |
0 | $0 | 11,939,402 (Direct) |
View |
Ownership |
2021-07-09 8:09 pm |
N/A 2031-07-01 |
Eledon Pharmaceuticals Inc. | ELDN | Hillson Jan Director |
0 | $0 | 40,000 (Direct) |
View |
| 2021-05-03 Option Award |
2021-05-04 4:27 pm |
N/A 2031-05-03 |
Eledon Pharmaceuticals Inc. | ELDN | Smith Bryan E. See Remarks |
158,500 | $0 | 158,500 (Direct) |
View |
Ownership |
2021-03-19 07:00 am |
N/A 2031-03-15 |
Eledon Pharmaceuticals Inc. | ELDN | Little Paul Sean CHIEF FINANCIAL OFFICER |
0 | $0 | 160,000 (Direct) |
View |
| 2020-12-22 Conversion |
2020-12-28 4:47 pm |
N/A N/A |
Eledon Pharmaceuticals Inc. | NVUS | BVF PARTNERS L P BIOTECHNOLOGY VALUE FUND L P BVF I GP LLC BIOTECHNOLOGY VALUE FUND II LP BVF II GP LLC Biotechnology Value Trading Fund OS LP BVF Partners OS Ltd. BVF GP HOLDINGS LLC BVF INC LAMPERT MARK N See Explanation of Responses |
1,312,841 | $0 | 369,941 (Direct) |
View |
Ownership |
2020-12-14 4:05 pm |
N/A 2030-12-08 |
Novus Therapeutics Inc. | NVUS | Lee June Director |
0 | $0 | 40,000 (Direct) |
View |
Ownership |
2020-11-06 6:36 pm |
N/A N/A |
Novus Therapeutics Inc. | NVUS | Logos Global Management LP 10% Owner |
0 | $0 | 1,260,722 (Indirect) |
View |
Ownership |
2020-10-05 7:53 pm |
N/A N/A |
Novus Therapeutics Inc. | NVUS | BVF PARTNERS L P BIOTECHNOLOGY VALUE FUND L P BVF I GP LLC BIOTECHNOLOGY VALUE FUND II LP BVF II GP LLC Biotechnology Value Trading Fund OS LP BVF Partners OS Ltd. BVF GP HOLDINGS LLC BVF INC LAMPERT MARK N 10% Owner |
0 | $0 | 7,165,667 (Direct) |
View |
Ownership |
2020-09-24 7:44 pm |
N/A 2030-09-14 |
Novus Therapeutics Inc. | NVUS | Perrin Steven See Remarks |
0 | $0 | 395,146 (Direct) |
View |
Ownership |
2020-09-24 7:44 pm |
N/A 2027-08-31 |
Novus Therapeutics Inc. | NVUS | Ogier Walter C Director |
0 | $0 | 102,758 (Direct) |
View |
| 2020-09-11 Option Award |
2020-09-15 8:18 pm |
N/A 2030-09-11 |
Novus Therapeutics Inc. | NVUS | LYONS GARY A Director |
1,167 | $0 | 1,167 (Direct) |
View |
| 2020-09-11 Option Award |
2020-09-15 8:13 pm |
N/A 2030-09-11 |
Novus Therapeutics Inc. | NVUS | Kuwahara Jon See Remarks |
2,145 | $0 | 2,145 (Direct) |
View |
| 2020-09-11 Option Award |
2020-09-15 8:12 pm |
N/A 2020-09-11 |
Novus Therapeutics Inc. | NVUS | Gros David-Alexandre C Chief Executive Officer |
18,278 | $0 | 18,278 (Direct) |
View |
| 2020-09-11 Option Award |
2020-09-15 8:10 pm |
N/A 2030-09-11 |
Novus Therapeutics Inc. | NVUS | Katkin Keith Director |
5,907 | $0 | 5,907 (Direct) |
View |
| 2020-09-11 Option Award |
2020-09-15 8:10 pm |
N/A 2030-09-11 |
Novus Therapeutics Inc. | NVUS | McBride John S. Director |
1,167 | $0 | 1,167 (Direct) |
View |